课题基金 / 基金详情

Role of the Programmed Death Ligand 1 (PD-L1) immune checkpoint in the acquisition of malignant phenotypes in tumour cells

Role of the Programmed Death Ligand 1 (PD-L1) immune checkpoint in the acquisition of malignant phenotypes in tumour cells
程序性死亡配体 1 (PD-L1) 免疫检查点在肿瘤细胞恶性表型获得中的作用
批准号：
368311
负责人：
Minassian Lori
金额：
$0.05万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-07-01 至 2018-07-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=368311&lang=en
关键词：
Cancer Drug Resistance Immune Checkpoint Metastasis Oncogenic Signaling

项目摘要

项目成果

Minassian Lori的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
There are many barriers to successful cancer treatment, including the ability of cancer cells to resist immune destruction and chemotherapy. Normally, immune cells can recognize cancer cells and destroy them. However, tumour cells can evade immune-mediate
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of the Programmed Death Ligand 1 (PD-L1) immune checkpoint in the acquisition of malignant phenotypes in tumour cells
Investigating an immune checkpoint mechanism linked to drug resistance in cancer cells
海外基金